Australian pharmaceutical policy: Price control, equity, and drug innovation in Australia

Journal of Public Health Policy

Volumn 29, Issue 1, 2008, Pages 106-120

  Doran, Evan ^a,b   Henry, David Alexander ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

^b Discipline of Clinical Pharmacology

Author keywords

Equity; Innovation; Pharmaceutical policy; Price control

Indexed keywords

ARTICLE; AUSTRALIA; COST; COST CONTROL; DRUG INDUSTRY; ECONOMICS; EXPERIMENTAL THERAPY; HEALTH CARE POLICY; HUMAN; INTERNATIONAL COOPERATION; ORGANIZATION AND MANAGEMENT; PUBLIC HEALTH; UNITED STATES;

AUSTRALIA; COST CONTROL; COSTS AND COST ANALYSIS; DRUG INDUSTRY; HEALTH POLICY; HUMANS; INTERNATIONAL COOPERATION; NATIONAL HEALTH PROGRAMS; THERAPIES, INVESTIGATIONAL; UNITED STATES;

EID: 41249100786     PISSN: 01975897     EISSN: 1745655X     Source Type: Journal    
DOI: 10.1057/palgrave.jphp.3200170     Document Type: Article

References (48)

1. Sell S. The quest for global governance in intellectual property and public health: structural, discursive and institutional dimensions. Paper Prepared for International Studies Association Conference Montreal, Canada, 17-20 March 2004. Available at http://cyber.law.harvard.edu/ blogs/gems/politicshiv/sell.pdf, last accessed 14 April 2007.
2. Sweeney K. Review of findings: Australian pharmaceutical pricing in the global context. Working Paper No. 19 (Final) Pharmaceutical Industry Project Working Paper Series. Centre for Strategic Economic Studies, Victoria University of Technology, 2004. Available at http://www.cfses.com, last accessed 14 April 2007.
3. Faunce T, Doran E, Henry D, Drahos P, Searles A, Pekasky B, et al. Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy. Globalization Health. 2005;1:15.
4. Salkeld G, Mitchell A, Hill S. Pharmaceuticals. In: Mooney G, Scotton R, editors. Economics and Australian Health Policy. Australia: Allen and Unwin; 1998, p. 115-36.
5. Hassett KA. Price Controls and the Evolution of Pharmaceutical Markets Draft Paper American Enterprise Institute 2004. Available at https://www.who.int/intellectualproperty/news/en/Submission-Hassett. pdf, accessed 16 October 2006.
6. Lofgren H, De Boer R. Pharmaceuticals in Australia: developments in regulation and governance. Soc Sci Med. 2004;58:2397-407.
7. Productivity Commission. International pharmaceutical price differences. Research Report. Ausinfo, Canberra. Available at http://www.pc.gov.au/study/pbsprices/finalreport/index.html, 2001.
8. Productivity Commission. Evaluation of the pharmaceutical industry investment program. Research Report. Ausinfo, Canberra. Available at http://www.pc.gov.au/study/piip/finalreport/index.html, 2003.
9. Dalton A. Australia's pharmaceutical benefits system: flawed but improving, and better than anywhere else. Austral Health Rev. 2001; 24(2):7-14.
10. Richardson J. Priorities of health policy: cost shifting or population health. Working Paper 147. Centre for Health Economics, Monash University, Melbourne 2004. Available at http://www.buseco.monash.edu.au/centres/che/pubs/ wp147.PDF.
11. Harvey K, Murray M. Medicinal drug policy. In: Gardner H, editor. The Politics of Health, 2nd edition. Melbourne: Churchill Livingstone; 1995, p. 238-83.
12. Davey P, Lees M, Aristides M, Ziss S. Report on the Australian System of Pharmaceutical Financing and Delivery. Efficiency and Equity Implications of Public versus Private Funding of Pharmaceuticals, vol. 1. Australia: Medical Technology Assessment Group; 1999.
13. Davey P, Lees M, Aristides M. Report on the Australian system of pharmaceutical financing and delivery. Cost-effectiveness of pharmaceuticals, vol. 2. Australia: Medical Technology Assessment Group; 1999.
14. Productivity Commission. Impact of advances in medical technology on Australia. Research Report. Melbourne. Available at http://www.pc.gov.au/ study/medicaltechnology/finalreport/medicaltechnology.pdf, 2005.
15. Calfee JE. Prices, Markets and the Pharmaceutical Revolution. AEI: Washington DC; 2000.
16. Danzon PM. Pharmaceutical Price Regulation; National Policies versus Global Interests. Washington, DC: American Enterprise Institute; 1997.
17. Kemp R. Australia's 'free-ride' in pharmaceuticals: can it last? Austral Health Rev. 1996;19:81-93.
18. Sheehan P. Pharmaceuticals and public policy: an assessment of the Productivity Commission Draft Report. A submission to the Productivity Commission. Centre for Strategic Economic Studies, Victoria University of Technology 2003. Available at http://www.cfses.com.
19. Schneerman K. The pharmaceuticals industry: prescription for the health and wealth of the nation. Australian Chief Executive, July 2003: 38-40.
20. Sheehan P. Pharmaceuticals, health and industry development: strategic issues and options. Pharmaceutical Industry Project Equity, Sustainability and Industry Development Working Paper Series, Working Paper No. 13. Centre for Strategic Economic Studies 2002. Available at http://www.cfses.com.
21. Rasmussen B. Innovation and industry structure in the biomedical industry: some preliminary results. Working Paper No. 17 (Final Draft). Pharmaceutical Industry Project Working Paper Series. Centre for Strategic Economic Studies, Victoria University of Technology, 2004a. Available at http://www.cfses.com.
22. Rasmussen B. Alliance opportunities for AusBiotech. Pharmaceutical Industry Project Working Paper Series, Working Paper No. 23. Centre for Strategic Economic Studies, 2004b. Available at http://www.cfses.com.
23. Rasmussen B. Developing the biomedical industries in Canada and Australia: an innovation systems approach. Working Paper No. 24, Pharmaceutical Industry Project Working Paper Series. Centre for Strategic Economic Studies, Victoria University of Technology, 2005. Available at http://www.cfses.com.
24. Coombs R, Metcalfe S J. Innovation in pharmaceuticals: perspectives on the co-ordination, combination and creation of capabilities. Technol Anal Strat Manage. 2002;14(3):261-71
25. McKelvey M, Orsenigo L. Pharmaceuticals as a sectoral innovation system. Paper prepared for the ESSY Project (European Sectoral Systems of Innovation) and within the Epris Project 2001. Available at http://www.druid.dk/ conferences/winter2002/gallery/orsenigo.PDF.
26. Gassmann O, Reepmeyer G. Organizing pharmaceutical innovation: from science-based knowledge creators to drug-oriented knowledge brokers. Creat Innovat Manage. 2005;14(3):233-45.
27. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003:22(2): 151-185.
28. Barton JH, Emmanuel EJ. The patents-based pharmaceutical development process: rationale problems and potential reforms. JAMA. 2005;294(16):2075-82.
29. Sharma A, Lacey N. Linking product development outcomes to market valuation of the firm: the case of the U.S. pharmaceutical industry. J Prod Innovat Manage. 2004;21:297-308.
30. Orsenigo L, Pammolli F, Riccaboni M. Technological change and network dynamics: lessons from the pharmaceutical industry. Res Pol. 2001;30:485-508.
31. Pammolli F, Riccaboni M. Market structure and innovation. Health Affairs. 2004;23(1):48-50.
32. Wagner JL, McCarthy E. International differences in drug prices. Annu Rev Pub Health. 2004;25:475-95.
33. Lacetera N, Orsenigo L. Political regimes, technological regimes and innovation in the evolution of the pharmaceutical industry in the USA and in Europe. Paper prepared for the "Conference on Evolutionary Economics", Johns Hopkins University, Baltimore, 30-31 March 2001. Available at http://www.fgcasal.org/politicafarmaceutica/ docs/ Nicola_Lacetera_and_Luigi_Orsenigo.PDF.
34. Acemoglu D, Linn J. Market size in innovation: theory and evidence from the pharmaceutical industry. Quart J Econ. August 2004;199:1049-1090.
35. McKelvey M, Orsenigo L. Pharmaceuticals as sectoral innovation system. Paper prepared for the ESSY Project (European Sectoral Systems of Innovation), 2001. Available at http://www.druid.dk/ conferences/winter2002/ gallery/orsenigo.PDF.
36. Light DW, Lexchin J. Foreign free riders and the high price of US medicines. Br Med J. 2005;331:958-60.
37. Love J. Evidence Regarding Research and Development Investments in Innovative and Non-Innovative Medicines, 2003. Available at http://www.cptech. org/ip/health/rnd/evidenceregardingrnd.pdf.
38. Wright DJ, Profitability and leakage under the PBS Australian Review of Public Affairs, 2003. Available at http://www.australianreview.net/digest/2003/ 12/wright.html.
39. Wright DJ. The drug bargaining game: pharmaceutical regulation in Australia. J Health Econ. 2004;23(4):785-813.
40. Grattan M, Stafford A. US drug companies eye Australia. The Age, 29 August 2006.
41. Sutherland T. US envoy targets trade issues. The Australian Financial Review, 29 August 2006.
42. Mecurio B. The impact of the Australia United States Free Trade Agreement on the provision of health services in Australia. Whittier Law Rev. 2005:26:1051.
43. Haynes S. The triumph is in the text: Australia - United States Free Trade Agreement: new opportunities and impacts. Available at http:// www.apec.org.au/docs/fta04Haynes.pdf.
44. Drahos P, Lokuge B, Faunce T, Goddard M, Henry D. Pharmaceuticals, intellectual property and free trade: the case of the US-Australia free trade agreement. Prometheus. 2004:22(3):243-57.
45. Lokuge B, Faunce TA. Trade disputes and the pharmaceutical benefits scheme: constructive ambiguities, non-violation nullification disputes and the Australia-United States Free Trade Agreement. Working Paper Centre for Governance of Knowledge and Development, 2004. Available at http://cgkd.anu.edu. au/menus/PDFs/TradedisputesandthePharmaceuticalBenefitsScheme.pdf.
46. Harvey KJ, Faunce TA, Lokuge B, Drahos P. Will the Australia-United States Free Trade Agreement undermine the pharmaceutical benefits scheme? Med J Aust. 2004;181(5):256
47. Surel Y. The role of cognitive and normative frames in policy-making. J European Pub Pol. 2000;7(4):495-512.
48. Campbell JL. Ideas, politics and public policy. Annu Rev Sociol. 2002; 28:21-38.